Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation

Cancer Biology and Therapy

Volumn 12, Issue 5, 2011, Pages 458-465

  Jeong, Woo Jin ^a   Mo, Ji Hun ^b   Park, Min Woo ^a   Choi, Ik Joon ^a   An, Soo Youn ^a   Jeon, Eun Hee ^a   Ahn, Soon Hyun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Dankook University   (South Korea)

Author keywords

BRAF protein; Differentiated thyroid cancer; Molecular targeted therapy; Papillary thyroid carcinoma; Ret PTC oncoprotein; SU11248; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN PATCHED; PROTEIN RET; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; IMMUNOBLOTTING; LOW DRUG DOSE; MOUSE; NONHUMAN; PAPILLARY THYROID CARCINOMA; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TREATMENT DURATION;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; MAP KINASE KINASE KINASES; MICE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRROLES; RAF KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052378137     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.5.16303     Document Type: Article

References (29)

1. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular and anaplastic: a morphological and epidemiological study. Endocr Pathol 2007; 18:1-7; PMID: 17652794; DOI: 10.1007/s12022-007-0002-z.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States 1973-2002. JAMA 2006; 295:2164-7; PMID: 16684987; DOI: 10.1001/ jama.295.18.2164.
3. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007; 8:148-56; PMID: 17267329; DOI: 10.1016/S1470-2045(07)70034-7.
4. Romagnoli S, Moretti S, Voce P, Puxeddu E. Targeted molecular therapies in thyroid carcinoma. Arq Bras Endocrinol Metabol 2009; 53:1061- 73; PMID: 20126863; DOI: 10.1590/S0004- 27302009000900002.
5. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91:2892-9; PMID: 16684830; DOI: 10.1210/jc.2005-838.
6. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996; 172:692-4; PMID: 8988680; DOI: 10.1016/S0002- 9610(96)00310-8.
7. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 2008; 62:559-63; PMID: 18725177; DOI: 10.1016/j.biopha. 2008.07.056.
8. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-96; PMID: 17327610; DOI: 10.1200/ JCO.2006.06.3602.
9. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009; 45:765-73; PMID: 19157861; DOI: 10.1016/j.ejca.2008.12.010.
10. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714-9; PMID: 18541894; DOI: 10.1200/ JCO.2008.16.3279.
11. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675-84; PMID: 19255327; DOI: 10.1200/JCO.2008.18.2717.
12. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161:923-31; PMID: 19773371; DOI: 10.1530/EJE-09-0702.
13. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359:31-42; PMID: 18596272; DOI: 10.1056/ NEJMoa075853.
14. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26:4708-13; PMID: 18541897; DOI: 10.1200/ JCO.2007.15.9566.
15. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11:962-72; PMID: 20851682; DOI: 10.1016/S1470-2045(10)70203-5.
16. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16:5260-8; PMID: 20847059; DOI: 10.1158/1078-0432.CCR-10-0994.
17. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95:2588-95; PMID: 20392874; DOI: 10.1210/jc.2009-1923.
18. Bagi CM, Christensen J, Cohen DP, Roberts WG, Wilkie D, Swanson T, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther 2009; 8:856-65; PMID: 19458500; DOI: 10.4161/cbt.8.9.8246.
19. Preto A, Goncalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, et al. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 2009; 9:387; PMID: 19878585; DOI: 10.1186/1471-2407-9-387.
20. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91:4070-6; PMID: 16849418; DOI: 10.1210/jc.2005-845.
21. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM. Sunitinib inhibits MEK/ ERK and SAPK/JNK pathways and increases sodium/ iodide symporter expression in papillary thyroid cancer. Thyroid 2010; 20:965-74; PMID: 20629553; DOI: 10.1089/thy.2010.0008.
22. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 1994; 123:331-7; PMID: 8133143.
23. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, et al. The RET/PTC-RASBRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-81; PMID: 15761501.
24. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38-46; PMID: 17520704; DOI: 10.1002/ cncr.22754.
25. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19:1351-61; PMID: 19895341; DOI: 10.1089/ thy.2009.0240.
26. Ohta K, Pang XP, Berg L, Hershman JM. Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab 1996; 81:2607-12; PMID: 8675585; DOI: 10.1210/ jc.81.7.2607.
27. Ohta K, Pang XP, Berg L, Hershman JM. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 1997; 82:2633-8; PMID: 9253346; DOI: 10.1210/ jc.82.8.2633.
28. Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, Wang M, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg 2008; 134:190-7; PMID: 18283163; DOI: 10.1001/archoto.2007.36.
29. Koh CS, Ku JL, Park SY, Kim KH, Choi JS, Kim IJ, et al. Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-transretinoic acid and mutations in the BRAF gene. Mol Cell Endocrinol 2007; 264:118-27; PMID: 17134824; DOI: 10.1016/j.mce.2006.10.017.